OBJECTIVE -To study trough levels of metformin in serum and its intra-individual variation in patients using a newly developed assay.
M
etformin is an insulin sensitizer used for treating type 2 diabetes, and the treatment is only rarely complicated by lactic acidosis. The substance is cleared from the blood through the kidneys (1) , and impaired renal function may lead to accumulation.
We have combined new technologies: liquid chromatography-tandem mass spectrometry (LCMSMS) and hydrophilic interaction liquid chromatography (2) in the development of a novel method for determination of metformin in serum. The aim was to study trough levels of metformin in type 2 diabetic patients and to assess intra-individual variations in patients with renal impairment. were studied at weeks 0, 2, 4, and 8. Serum metformin, cystatin C, and creatinine were analyzed in both groups. All participants provided informed consent, and the study was approved by the local ethics committee.
RESEARCH DESIGN AND METHODS

Method for analysis of metformin
One part serum was mixed with 10 parts internal standard fortified acetonitril. After centrifugation, one part of the supernatant was diluted with 20 parts of the mobile phase. Then 5 l of the diluted supernatant was injected into the liquid chromatograph.
The mobile phase is a mixture of water, acetonitril, formic acid, and ammonium acetate (pH 2-3). It elutes fenformin and metformin after 2 and 3 min, respectively, from the HILIC column (Merck SeQuant, Umea, Sweden). The mobile phase enters the mass spectrometer, and positively ionized molecules of the eluted compounds are formed by electro spray ionization (3). The positively ionized molecules are fragmented by collision with nitrogen (3) to form fragments with the mass/ charge of 70.8 and 105.2 for metformin and fenformin, respectively. The intensity of these fragments are measured and calculated to represent concentration data of metformin.
We used a standard high-performance liquid chromatograph combined with a triple quadruple mass spectrometer (Sciex API 4000; Applied Biosystems, Carlsbad, CA). The chromatographic separation of metformin and its internal standard fenformin was performed with isocratic HILIC elution.
1,1-Dimethylbiguanide hydrochloride and fenformin hydrochloride (SigmaAldrich, St. Louis, MO) were used as a reference substance for metformin and internal standard in the assay, respectively.
The lower threshold for detection is 0.05 mol/l, and the results are linear between 0.05 and 125 mol/l. At concentrations Ͼ125 mol/l the sample is diluted. Coefficient of variation (CV) percentage during 20 months is 12% at the 3.6 mol/l level and 6.3% at the 33 mol/l level, with 56 samples at each level.
Estimation of GFR Estimation of GFR was based on cystatin C (4 -6) determined by an immunoturbidimetric method on a Hitachi Modular P analysis system. Use of creatinine for estimating GFR did not change the results of the study (data not shown).
Statistical analysis
Results are given as median values and range or interquartile range. SPSS 15.0 was used. Wilcoxon rank-sum (P Ͻ 0.05) and Spearman nonparametric tests (P Ͻ 0.05) were used when appropriate.
RESULTS
Trough levels in relation to renal function Of the 137 patients, 9 had an eGFR Ͻ30 ml/min/1.73 m 2 and a median trough value of S-metformin at 8.88 mol/l (range 5.99 -18.60); 21 patients had an eGFR of 30 -60 ml/min/1.73 m 2 and a median S-metformin of 7.71 mol/l (range 0.12-15.15); and 107 patients had an eGFR of Ͼ60 ml/min/1.73m 2 and a median S-metformin of 4.5 mol/l (range 0.1-20.7). The median doses of metformin were 1,500 mg (1,000 -3,000), 1,500 mg (500 -3,000), and 1,500 mg (500 -3,000) for each group, respectively (Fig. 1) .
Intra-individual variance of metformin concentrations
The median intra-individual variation of the S-metformin level in the 20 patients during the 8-week period with repeated measurements was CV 29.4% (range 9.8 -74.2). Of the 20 patients, 6 had an eGFR Ͻ30 ml/min/1.73 m 2 , and 14 had an eGFR 30 -63 ml/min/1.73 m 2 . Median Smetformin was 10 mol/l (interquartile range 5.3-16). There was no correlation between CV of S-metformin and GFR (r ϭ 0.3131, P ϭ 0.156).
The CV of the four eGFR values was 7.5% (range 5.9 -12.5). Median eGFR at weeks 0, 2, 4, and 8 was 37, 34, 36, and 33, respectively. There was a significant difference between the first (week 0) and last (week 8) median value of eGFR (P ϭ 0.023).
CONCLUSIONS -It is widely acknowledged that metformin therapy is beneficial in treating type 2 diabetes and should be made available to as many patients as possible. One obstacle to this has been the possible risk of lactic acidosis in patients with impaired renal function. We have had seven cases of patients on treatment with metformin admitted with lactic acidosis with metformin levels ranging from 256 to 682 mol/l (median 330). These data suggest that high levels of se- rum metformin are needed to cause lactic acidosis.
Prevailing clinical experience has led to recommendations that metformin may be used at eGFR above 30 ml/min/1.73 m 2 (7,8). Our study supports these guidelines showing that patients above this GFR limit rarely had metformin levels above 20 mol/l, which seems to be a safe level.
If the current guidelines gain general recognition it becomes even more important to advocate cessation of metformin therapy when renal failure develops abruptly or in our opinion with any severe disease, especially when there is risk of dehydration.
Results from this study show a considerable intra-individual CV of 29.4% for metformin concentrations in 20 patients with impaired renal function.
There was a wide range (10 -74%) of variability, with only four participants having CVs below 20%. This variability probably reflects the heterogeneity of the study population. The wide intra-individual variation seen in this study probably also exists in daily clinical practice.
Based on these findings we propose that:
• eGFR should be used to estimate renal function in patients using metformin.
• LCMSMS can be used as a routine method to evaluate trough serum concentrations of metformin and that 20 mol/l may be used as preliminary upper therapeutic limit.
• when intra-individual CV is high, the technique is less suitable for dose titration.
• LCMSMS may help to differ between metformin-associated lactic acidosis and other causes.
